Crow Point Partners’s NovoCure NVCR Stock Holding History

Crow Point Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,410	Closed	-$324K	–	118
2019 Q3	$324K	Sell	4,410 -800	-15%	-$64K	0.05%	85
2019 Q2	$329K	Sell	5,210 -1,950	-27%	-$98.8K	0.05%	78
2019 Q1	$345K	Sell	7,160 -9,033	-56%	-$435K	0.06%	77
2018 Q4	$532K	Sell	16,193 -1,125	-6%	-$41.1K	0.1%	55
2018 Q3	$907K	Sell	17,318 -1,112	-6%	-$44.3K	0.16%	54
2018 Q2	$573K	Buy	18,430 +12,959	+237%	+$360K	0.11%	67
2018 Q1	$119K	Sell	5,471 -384	-7%	-$8.26K	0.02%	124
2017 Q4	$120K	Buy	+5,855	New	+$113K	0.02%	160

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCP

Darsana Capital Partners New York $22.3B AUM 42.01% 1-Year Est. Return

Crow Point Partners's NVCR Position: Q4 2019 in Review

Crow Point Partners sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 4,410 shares — an estimated $324K sold.

Crow Point Partners first reported a position in NVCR in Q4 2017 and held it in 8 quarters. The position peaked at $907K in Q3 2018. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Crow Point Partners reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
Crow Point Partners sold 4,410 NovoCure shares in Q4 2019, an estimated $324K.
Crow Point Partners first reported a position in NovoCure in Q4 2017 and held it in 8 quarters.
Crow Point Partners's NovoCure position peaked at $907K in Q3 2018.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.